Known as the pharmacy of the world, India supplies nearly 20% of global generic volume and more than 60% of global vaccines. The country also boasts the highest number of FDA-compliant plants outside the US. Over the past five years, its pharmaceutical exports have been steadily increasing—from around $20-21 billion in the pre-pandemic period to $30.47 billion in FY25, marking a growth of over 9% year-on-year, according to official data.
More than 60% of its pharma shipments are directed to highly regulated markets, with the US accounting for roughly one-third of exports, followed by Europe and other regulated and emerging markets. Experts attribute the export growth to sustained demand for generics, vaccines, and specialty products, despite pricing pressures in some key segments.
